NGL Fine-Chem Limited (NGLFINE) - Net Assets
Based on the latest financial reports, NGL Fine-Chem Limited (NGLFINE) has net assets worth Rs3.00 Billion INR (≈ $32.47 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Rs4.84 Billion ≈ $52.36 Million USD) and total liabilities (Rs1.84 Billion ≈ $19.89 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of NGL Fine-Chem Limited to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Rs3.00 Billion |
| % of Total Assets | 62.01% |
| Annual Growth Rate | 22.53% |
| 5-Year Change | 82.86% |
| 10-Year Change | 538.78% |
| Growth Volatility | 12.65 |
NGL Fine-Chem Limited - Net Assets Trend (2009–2025)
This chart illustrates how NGL Fine-Chem Limited's net assets have evolved over time, based on quarterly financial data. Also explore NGLFINE total assets for the complete picture of this company's asset base.
Annual Net Assets for NGL Fine-Chem Limited (2009–2025)
The table below shows the annual net assets of NGL Fine-Chem Limited from 2009 to 2025. For live valuation and market cap data, see NGL Fine-Chem Limited (NGLFINE) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | Rs2.82 Billion ≈ $30.54 Million |
+7.54% |
| 2024-03-31 | Rs2.63 Billion ≈ $28.40 Million |
+18.01% |
| 2023-03-31 | Rs2.23 Billion ≈ $24.07 Million |
+9.51% |
| 2022-03-31 | Rs2.03 Billion ≈ $21.98 Million |
+31.57% |
| 2021-03-31 | Rs1.54 Billion ≈ $16.70 Million |
+56.08% |
| 2020-03-31 | Rs989.61 Million ≈ $10.70 Million |
+7.42% |
| 2019-03-31 | Rs921.23 Million ≈ $9.96 Million |
+27.87% |
| 2018-03-31 | Rs720.42 Million ≈ $7.79 Million |
+23.12% |
| 2017-03-31 | Rs585.12 Million ≈ $6.33 Million |
+32.34% |
| 2016-03-31 | Rs442.15 Million ≈ $4.78 Million |
+34.73% |
| 2015-03-31 | Rs328.16 Million ≈ $3.55 Million |
+33.70% |
| 2014-03-31 | Rs245.44 Million ≈ $2.65 Million |
+22.62% |
| 2013-03-31 | Rs200.15 Million ≈ $2.16 Million |
+17.01% |
| 2012-03-31 | Rs171.06 Million ≈ $1.85 Million |
+6.52% |
| 2011-03-31 | Rs160.59 Million ≈ $1.74 Million |
+17.66% |
| 2010-03-31 | Rs136.48 Million ≈ $1.48 Million |
+24.82% |
| 2009-03-31 | Rs109.35 Million ≈ $1.18 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NGL Fine-Chem Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4868.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Rs2.77 Billion | 98.12% |
| Common Stock | Rs30.89 Million | 1.09% |
| Other Comprehensive Income | Rs20.93 Million | 0.74% |
| Other Components | Rs1.17 Million | 0.04% |
| Total Equity | Rs2.82 Billion | 100.00% |
NGL Fine-Chem Limited Competitors by Market Cap
The table below lists competitors of NGL Fine-Chem Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
IFGL Refractories Limited
NSE:IFGLEXPOR
|
$147.97 Million |
|
Igis Value Plus Reit Co Ltd
KO:334890
|
$147.99 Million |
|
Indigo Acquisition Corp. Ordinary Shares
NASDAQ:INAC
|
$147.99 Million |
|
American Rare EARTHS Ltd
AU:ARR
|
$148.01 Million |
|
LONCOR GOLD INC.
F:LO5
|
$147.91 Million |
|
Centrum Medyczne ENEL-MED SA
WAR:ENE
|
$147.88 Million |
|
Areeya Property Public Company Limited
BK:A
|
$147.84 Million |
|
Purit Co. Ltd.
KQ:445180
|
$147.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NGL Fine-Chem Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,626,319,000 to 2,824,346,000, a change of 198,027,000 (7.5%).
- Net income of 211,243,000 contributed positively to equity growth.
- Dividend payments of 10,812,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Rs211.24 Million | +7.48% |
| Dividends Paid | Rs10.81 Million | -0.38% |
| Other Changes | Rs-2.40 Million | -0.09% |
| Total Change | Rs- | 7.54% |
Book Value vs Market Value Analysis
This analysis compares NGL Fine-Chem Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.84x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 125.12x to 4.84x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-03-31 | Rs17.70 | Rs2214.50 | x |
| 2010-03-31 | Rs22.09 | Rs2214.50 | x |
| 2011-03-31 | Rs25.99 | Rs2214.50 | x |
| 2012-03-31 | Rs27.69 | Rs2214.50 | x |
| 2013-03-31 | Rs32.40 | Rs2214.50 | x |
| 2014-03-31 | Rs39.73 | Rs2214.50 | x |
| 2015-03-31 | Rs53.12 | Rs2214.50 | x |
| 2016-03-31 | Rs71.57 | Rs2214.50 | x |
| 2017-03-31 | Rs94.71 | Rs2214.50 | x |
| 2018-03-31 | Rs116.61 | Rs2214.50 | x |
| 2019-03-31 | Rs149.11 | Rs2214.50 | x |
| 2020-03-31 | Rs160.18 | Rs2214.50 | x |
| 2021-03-31 | Rs250.01 | Rs2214.50 | x |
| 2022-03-31 | Rs328.94 | Rs2214.50 | x |
| 2023-03-31 | Rs360.23 | Rs2214.50 | x |
| 2024-03-31 | Rs425.11 | Rs2214.50 | x |
| 2025-03-31 | Rs457.09 | Rs2214.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NGL Fine-Chem Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 7.48%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.74%
- • Asset Turnover: 0.85x
- • Equity Multiplier: 1.53x
- Recent ROE (7.48%) is below the historical average (18.02%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 15.39% | 6.83% | 1.21x | 1.86x | Rs5.90 Million |
| 2010 | 19.82% | 9.72% | 1.10x | 1.86x | Rs13.40 Million |
| 2011 | 15.04% | 6.89% | 1.07x | 2.05x | Rs8.10 Million |
| 2012 | 6.12% | 2.90% | 0.97x | 2.17x | Rs-6.64 Million |
| 2013 | 14.53% | 5.24% | 1.17x | 2.37x | Rs9.08 Million |
| 2014 | 18.45% | 5.74% | 1.41x | 2.28x | Rs20.74 Million |
| 2015 | 25.38% | 9.43% | 1.33x | 2.03x | Rs50.48 Million |
| 2016 | 25.78% | 11.84% | 1.24x | 1.75x | Rs69.77 Million |
| 2017 | 24.34% | 14.22% | 0.99x | 1.73x | Rs83.88 Million |
| 2018 | 17.48% | 11.35% | 0.86x | 1.79x | Rs53.89 Million |
| 2019 | 21.85% | 13.35% | 1.06x | 1.54x | Rs109.15 Million |
| 2020 | 8.42% | 5.60% | 0.97x | 1.55x | Rs-15.61 Million |
| 2021 | 36.72% | 21.99% | 1.24x | 1.35x | Rs412.73 Million |
| 2022 | 24.55% | 15.72% | 1.15x | 1.36x | Rs295.76 Million |
| 2023 | 9.21% | 7.37% | 0.97x | 1.29x | Rs-17.59 Million |
| 2024 | 15.73% | 12.20% | 0.95x | 1.35x | Rs150.54 Million |
| 2025 | 7.48% | 5.74% | 0.85x | 1.53x | Rs-71.19 Million |
Industry Comparison
This section compares NGL Fine-Chem Limited's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $12,859,968,938
- Average return on equity (ROE) among peers: 23.42%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NGL Fine-Chem Limited (NGLFINE) | Rs3.00 Billion | 15.39% | 0.61x | $147.96 Million |
| GlaxoSmithKline Pharmaceuticals Limited (GLAXO) | $21.40 Billion | 20.81% | 0.83x | $4.28 Billion |
| Pfizer Limited (PFIZER) | $42.17 Billion | 18.20% | 0.16x | $2.33 Billion |
| Sanofi India Limited (SANOFI) | $10.14 Billion | 15.29% | 0.39x | $848.62 Million |
| SANOFI CONS HEALTHC IND L (SANOFICONR) | $2.73 Billion | 66.30% | 0.58x | $1.19 Billion |
| SENORES PHARMACEUTICALS L (SENORES) | $94.96 Million | 7.21% | 0.53x | $447.85 Million |
| TTK Healthcare Limited (TTKHLTCARE) | $620.96 Million | 12.68% | 1.22x | $138.16 Million |
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more